Celldex reports positive Phase 1 results for bispecific antibody CDX-622 in healthy participants

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.

CLDX

0.00
  • Celldex presented first-in-human Phase 1 results for bispecific antibody CDX-622 at the EAACI Annual Meeting.
  • Findings showed clear evidence of mast cell suppression consistent with the drug’s intended mechanism, supporting further development in inflammatory diseases.
  • The study reported a favorable tolerability profile across tested doses, with no major safety signals flagged.
  • CDX-622 is in a Phase 1b proof-of-mechanism study in mild to moderate asthma, with additional proof-of-concept studies planned in allergic rhinitis, food allergy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606140515PRIMZONEFULLFEED9746617) on June 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.